Skip to main content
ICUI logo

ICUI · Icu Medical Inc · Documents

Track ICUI — free
$176.53 -0.39 (-0.22%) Play latest call Q3 2026 earnings call transcript
Market Cap
$4.42B
Shares
25.01M
Volume · Nov 18 61.92K Avg daily vol (3M) 254.06K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $2.23B down 6.3% 10-K filed Feb 19, 2026 Quarterly report FY2026 Q3 Revenue $560.44M up 4.4% 10-Q filed Nov 5, 2026 Latest results Revenue and profit rise; fiscal-year guidance expected near high end 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
Q3 revenue grew 5% organically

ICU Medical reported Q3 revenue of $556 million, up 5% organically, with adjusted EBITDA of $114 million and adjusted EPS of $2.44; full-year guidance points toward the higher end of $415 to $435 million EBITDA and $8.60 to $9 EPS.

2 source passages
Revenue for Q3 was $556 million for total company growth of 5% on an organic basis, or 4% reported, as the reported results are no longer impacted by the mid-2025 creation of the Apsuka ICU Medical Joint Venture and the resulting deconsolidation of IV solutions from our income statement. Adjusted gross margins were strong at just over 42%, adjusted EBITDA improved to $114 million, and adjusted EPS was $2.44. And based on our performance in Q3 and our outlook for the remainder of the year, we now expect to finish the year towards the higher end of the previously provided guidance range of $415 to $435 million of EBITDA. And $8.60 to $9 for EPS. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Tariff refunds lift nine-month gross margin to 41.2%

ICU Medical, Inc. reported a 41.2% gross margin for the nine months ended September 30, 2026, up from 36.6%, with $29.2 million in tariff refunds boosting cost of goods sold.

Revenue $560.44M ▲ 4.4% Net income $26.85M Diluted EPS $1.07
Read from the MD&A section
3 source passages
ICU Medical, Inc. For the three and nine months ended September 30, 2026, gross margins were 41.9% and 41.2%, respectively, as compared to 37.4% and 36.6% for the same periods in the prior year. during the nine months ended September 30, 2026, $29.2 million of tariff refunds were recognized in cost of goods sold and $1.1 million of related interest income was recognized in interest expense, net. Open the document at this passage
Nov 5
Current report 8-K
Revenue and profit rise; fiscal-year guidance expected near high end

ICU Medical reported third-quarter GAAP revenue of $560.4 million and net income of $26.8 million, or $1.07 per diluted share. It reaffirmed fiscal year 2026 guidance and expects results near the high end.

Financial results
4 source passages
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2026. Third quarter 2026 GAAP revenue was $560.4 million, as compared to $537.0 million in the same period in the prior year. GAAP net income for the third quarter of 2026 was $26.8 million, or $1.07 per diluted share, as compared to GAAP net loss of $(3.4) million, or $(0.14) per diluted share, for the third quarter of 2025. The Company is reaffirming its full year 2026 guidance but expects to end the fiscal year towards the higher end of the guidance range. Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $551.68M ▲ 0.5% Net income $19.09M ▼ 46.0% Diluted EPS $0.76 ▼ 46.9%
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $530.23M ▼ 12.3% Net income $30.13M Diluted EPS $1.20
Apr 2
Proxy statement DEF 14A Meeting May 13, 2026
Proxy statement AI summary on its way
Feb 19
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $2.23B ▼ 6.3% Net income $732K Diluted EPS $0.03
2025
Feb 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $2.38B ▲ 5.4% Net loss $117.69M Diluted EPS -$4.83
2024
Showing 1–50 of 128 documents
Key facts CIK 883984 CUSIP 44930G107 13F (30d) 333 filings 298 filers Visit website Investor relations